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Abstract
 
Latent membrane protein 1 (LMP1) plays a critical role in B cell transformation by Epstein-Barr
virus (EBV) and appears to mimic a constitutively active CD40 receptor. Intracellular tumor
necrosis factor (TNF) receptor–associated factor (TRAF) adapter proteins, shown to contribute
to signaling by both CD40 and LMP1, were recruited by both molecules to lipid-enriched
membrane rafts. However, we found that TRAFs 2 and 3 were subsequently degraded after
CD40- but not LMP1-induced signaling. This degradation was proteasome-dependent and re-
quired direct TRAF binding by CD40. Using a model system designed to directly compare the
signaling potency of the cytoplasmic domains of LMP1 and CD40 in B lymphocytes, we found
 
that LMP1 more potently activates c-Jun kinase and nuclear factor 
 
k
 
B and induces higher levels
of several B cell effector functions than does CD40. This suggests that LMP1 utilizes a modified
CD40 signaling pathway. Failure to regulate TRAFs may contribute to the enhanced capacity
of LMP1 to activate B cells as well as promote B cell transformation.
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Introduction
 
EBV is a B lymphotropic human herpes virus that infects a
majority of the world’s population. EBV has been strongly
associated with the development of several human lympho-
proliferative conditions including posttransplant lymphopro-
liferative disease, AIDS-related lymphoma, Burkitt’s lymph-
oma, and Hodgkin’s disease (1). Of the nine EBV genes
expressed as proteins in EBV-transformed cell lines, latent
 
membrane protein 1 (LMP1)
 
1
 
 is the best characterized, and is
the only EBV-encoded gene product capable of transform-
ing cells in vitro (2). Additionally, LMP1 is essential for
transformation of EBV-infected B lymphocytes (3). To-
gether these data suggest a primary role for LMP1 in the de-
velopment of EBV-lymphoproliferative disorders.
Structurally, LMP1 is composed of a short NH
 
2
 
-terminal
cytoplasmic region, six transmembrane domains, and a sig-
naling COOH-terminal cytoplasmic tail. The NH
 
2
 
 termi-
nus and transmembrane domains appear responsible for
promoting constitutive activation by ligand-independent
oligomerization of LMP1, but are not required for signal-
ing per se (4, 5). The signaling COOH-terminal cytoplas-
mic tail of LMP1 appears to mimic many aspects of signal-
ing by CD40, an activating receptor normally expressed on
B lymphocytes (6–8). After ligation by its ligand CD154,
expressed on activated T cells, CD40 activates B cells by a
signaling pathway that begins with the association of
adapter proteins known as TNF receptor–associated factors
(TRAFs; reference 9). After binding CD40, TRAFs are
thought to interact with as yet uncharacterized signaling
 
proteins that link CD40 to nuclear factor (NF)-
 
k
 
B and
c-Jun kinase (JNK) activation. Similar to CD40, LMP1 also
binds TRAFs which are then thought to interact with ki-
nases such as NF-
 
k
 
B–inducing kinase (NIK; reference 10)
that ultimately promote activation of NF-
 
k
 
B.
TRAFs are a class of adapter proteins initially character-
ized by their ability to interact with the TNF receptor (for
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Abbreviations
 
 
 
used in this paper: 
 
CHO, Chinese hamster ovary; EMSA,
electrophoretic mobility shift assay; HRP, horseradish peroxidase; ICAM;
intercellular adhesion molecule; JNK, c-Jun kinase; LFA, lymphocyte
function–associated antigen; LMP, latent membrane protein; MCF, mean
channel fluorescence; NF, nuclear factor; TRAF, TNF receptor–associ-
ated factor; WT, wild-type. 
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a review, see reference 11). CD40 is reported to directly
bind TRAFs 2, 3, 5, and 6 (and can associate with TRAF1
via its heterodimerization with TRAF2), whereas LMP1 is
reported to bind TRAFs 1, 2, 3, and 5 (12–16). Different
TRAF proteins appear to play distinct roles in signaling
through CD40, LMP1, and other TNF receptor family
members. TRAF2 appears to be primarily required for
JNK activation and also contributes to NF-
 
k
 
B activation
by both molecules (12, 17, 18). TRAF2 also plays a role in
CD40-mediated surface molecule upregulation and IgM
secretion in B lymphocytes (19, 20). In contrast, TRAF3
may antagonize TRAF2’s effects in promoting NF-
 
k
 
B ac-
tivation and CD40-mediated IgM secretion (18, 20). The
TRAF binding domains of LMP1 have been shown to be
essential to its ability to transform B cells (21).
Despite similarities in CD40 and LMP1 signaling, differ-
ences have been noted in addition to differences in TRAF
utilization. When CD40-deficient mice were manipulated
to transgenically express the LMP1 gene under control of
the Ig promoter, they showed a B cell activation pheno-
type intermediate between that of wild-type (WT) and
CD40
 
2
 
/
 
2
 
 mice (8). This suggests that although LMP1
mimics some aspects of CD40 signaling, differences do ex-
ist. Additionally, we reported previously that CD40 and
LMP1 can cooperate in signaling, also indicating that
CD40 and LMP1 signaling pathways contain distinct fea-
tures (7).
Together, these data suggested the hypothesis that
CD40 and LMP1 utilize distinct signaling mechanisms to
affect B cell activation. As stated above, both molecules
initiate signaling at least in part via association with TRAF
adapter proteins. Additionally, it is known that LMP1 re-
cruits TRAF3 to lipid-rich membrane microdomains, or
rafts (22), and we have shown that upon CD40 ligation,
CD40 itself relocates to membrane rafts, as well as recruit-
ing TRAFs 2 and 3 to these complexes (23). Engagement
of several members of the TNFR family of molecules,
CD30 (24) and TNFR2 (25), results in degradation of
TRAF2, and we have recently reported that CD40 liga-
tion also stimulates TRAF2 loss (23). Remarkably, LMP1
signaling failed to induce TRAF degradation. As TRAF
degradation may be an important mechanism for regulat-
ing and limiting signal transduction, we were thus curious
to determine whether the signaling potency of CD40 and
LMP1 differs. Experiments using WT LMP1 molecules
and chimeric LMP1 molecules with CD40 cytoplasmic
domains indicated that the LMP1 cytoplasmic domain de-
livers stronger activation signals to the B cell. However,
because the transmembrane domains of LMP1 aggregate
and initiate signaling constitutively as the molecule is ex-
pressed, it was difficult to directly compare signaling be-
tween subclones expressing the WT or hybrid molecules.
To examine this question more carefully, we needed an
experimental system that would allow direct comparison of
signaling effectiveness.
Previous work using a chimeric molecule with the ex-
ternal domain of the class I molecule HLA-A2 demon-
strated that the COOH-terminal cytoplasmic tail of LMP1
is sufficient to initiate LMP1 signaling in B lymphocyte cell
lines (7), confirming earlier findings (26). When stimulated
by anti-A2 mAb the chimeric molecule faithfully replicated
every aspect of LMP1 signaling. However, use of this mol-
ecule did not permit a direct comparison of signaling po-
tencies of CD40 and LMP1 as different Abs (anti-CD40
versus anti-A2) were required to initiate signaling, and
might differ in their affinities and/or cross-linking ability.
To permit a direct comparison of the activity of the CD40
and LMP1 cytoplasmic tails in stimulating signaling, we
constructed a recombinant human CD40-LMP1 chimera.
Stable transfectants of B cell lines expressing similar levels
of either WT human (h)CD40 or the hCD40-LMP1 chi-
mera were produced. This chimera allowed us to use the
same type and level of stimulus to initiate signaling by mol-
ecules containing either cytoplasmic domain. We deter-
mined that both recruitment of TRAFs and their degrada-
tion is dependent on whether the cytoplasmic domain of
the molecule is from hCD40 or LMP1, verifying that it is
this domain of each molecule that determines its signaling
behavior. CD40-mediated TRAF degradation was found
to be proteasome dependent, require direct TRAF bind-
ing, and dominate over the inability of LMP1 to induce
degradation.
Using this model we also directly compared signaling ef-
fectiveness of the two cytoplasmic domains, and found that
the cytoplasmic domain of LMP1 more potently activates
B lymphocytes in both early and late measures of signaling,
including activation of JNK and NF-
 
k
 
B, upregulation of
surface molecules, and secretion of IL-6 and IgM. We pro-
pose that differential TRAF regulation contributes to the
observed differences in signaling potencies of the cytoplas-
mic domains of CD40 and LMP1, and may contribute to
the transforming activity of LMP1.
 
Materials and Methods
 
Cell Lines.
 
The mouse B cell lines CH12.LX (27) and
M12.4.1 (28) were maintained in RPMI 1640 with 10% FCS, 10
 
m
 
M 2-mercaptoethanol, and antibiotics. M12.4.1 cells were cho-
sen for analysis of surface molecule upregulation, because
CH12.LX cells have a higher background level of the surface
molecules studied, and thus are not optimal in this assay.
CH12.LX cells were chosen for analysis of IgM and IL-6 secre-
tion, as M12.4.1 cells produce little to no IL-6 or Ig after any
stimulus. Both cell lines activate both NF-
 
k
 
B and JNK after
CD40 and LMP1 signaling (7, 29), so both were tested in these
assays. Transfected B cell lines were maintained in culture me-
dium supplemented with 400 
 
m
 
g/ml G418 sulfate (Life Technol-
ogies). Human CD154-expressing Chinese hamster ovary
(CHO) cells were provided by Dr. A. Black (IDEC Pharmaceuti-
cals Corporation, San Diego, CA). Mouse CD154-expressing
CHO cells prepared in our laboratory have been described previ-
ously (30). CHO cells were maintained in DMEM with 10%
FCS, nonessential amino acids, and antibiotics.
 
Abs.
 
The mAbs 16\10A1 (FITC-labeled anti–B7-1, Arme-
nian hamster IgG), G235-2356 (FITC-hamster IgG isotype con-
trol, hamster IgG), HM40-3 (anti–mouse CD40, hamster IgM),
G235-1 (isotype control, hamster IgM), and C4 (anti–mouse ac-
tin, mouse IgG
 
1
 
) were purchased from BD PharMingen. Mouse 
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IgG
 
1
 
 isotype control mAb (MOPC-21) was purchased from
Sigma-Aldrich. Rabbit anti-TRAF1 (N-19), rabbit anti-TRAF2
(C-20), rabbit anti-TRAF3 (H-122), and rabbit anti-I
 
k
 
B
 
a
 
 (FL)
Abs were purchased from Santa Cruz Biotechnology, Inc. Sheep
polyclonal anti–glutathione 
 
S
 
-transferase (GST)–hCD40 (external
domain) Ab was prepared for us by Elmira Biologicals (Iowa
City, IA). Goat anti–rabbit horseradish peroxidase (HRP) and
goat anti–mouse HRP Abs were purchased from Bio-Rad Labo-
ratories. Donkey anti–sheep HRP Ab was purchased from Jack-
son ImmunoResearch Laboratories. The following Abs were
produced in our laboratory by hybridomas purchased from
American Type Culture Collection or were gifts of the indicated
individuals: anti-hCD40 (G28-5, mIgG
 
1
 
; American Type Cul-
ture Collection), anti-LMP1 (S-12, mIgG
 
2a
 
) from Dr. F. Wang
(Harvard Medical School, Boston, MA), anti–mouse CD40
(1C10, rat IgG
 
2a
 
) from Dr. F. Lund (Trudeau Institute, Saranac
Lake, NY), anti–mouse CD23 (clone B3B4, rat IgG
 
2a
 
), and anti–
mouse IgE (EM95.3, rat IgG
 
2a
 
 isotype control) from Dr. T.
Waldschmidt (University of Iowa, Iowa City, IA), anti–mouse
intercellular adhesion molecule (ICAM)-1 (YN1/1.7.4; Ameri-
can Type Culture Collection), anti–mouse lymphocyte function–
associated antigen (LFA)-1 (M17/4.4.11.9, rat IgG
 
2a
 
; American
Type Culture Collection), anti–mouse IL-6 hybridomas 20F3.11
(rat IgG; American Type Culture Collection) and 32C11.4 (rat
IgG
 
1
 
; American Type Culture Collection).
 
Chemicals.
 
Recombinant mouse IL-6 was purchased from
BD PharMingen. Octylglucoside and 
 
0
 
-phenylenediamide dihy-
drochloride tablets were purchased from Amersham Pharmacia
Biotech. MG132 proteasome inhibitor was purchased from Cal-
biochem. Isopropyl-
 
b
 
-
 
d
 
-thiogalactopyranoside (IPTG) was pur-
chased from Amresco.
 
DNA Constructs.
 
The generation of the WT-hCD40 expres-
sion plasmid and hCD40 structural mutants has been described
previously (19). PCR SOEing (31) was used to generate a direct
fusion between the first 215 amino acids of CD40 (extracellular
and transmembrane domains) and the terminal 200 amino acids of
LMP1 (cytoplasmic COOH terminus). The same technique was
used to generate a fusion between the membrane spanning exter-
nal domains of LMP1 and the cytoplasmic domain of hCD40.
DNA sequencing of the chimeric molecules confirmed that the
constructs were free of undesired mutations. Constructs expressed
inducibly contained LacR binding sites upstream of the cDNA
insertion site in the plasmid, and were transfected into subclones
of M12.4.1 and CH12.LX already stably constitutively expressing
LacR. Expression is induced by incubation in the presence of
IPTG. This expression system has been described previously (7).
 
Transfections.
 
Stable transfections of mouse B cell lines with
DNA constructs were conducted as described previously (32).
G418 resistant subclones were analyzed either for surface expres-
sion of hCD40 or hCD40-LMP1 using a FACScan™ flow
cytometer (Becton Dickinson), or by Western blotting for WT-
LMP1 and LMP1-hCD40, and expression-matched clones iso-
lated. B cell transfectants expressing mutant hCD40 molecules
have been described previously (19). All experiments presented
were performed with two to three individual stably transfected,
expression-matched subclones of each type analyzed.
 
TRAF Degradation Assays.
 
TRAF degradation after induced
expression of WT-LMP1 or LMP1-hCD40 was analyzed after
incubation of B cell transfectants with 100 
 
m
 
M IPTG for varying
time periods. TRAF degradation in transfectants expressing WT-
hCD40 or hCD40-LMP1 was determined by stimulating B cells
(10
 
7
 
) for 10 min, 30 min, 2 h, or 6 h with 1 
 
m
 
g/ml of either anti-
hCD40 (G28-5) or isotype control (MOPC-21) mAbs. Degrada-
 
tion induced via stimulation through endogenous mCD40 was as
above, using anti-mCD40 mAb (1C10) or its isotype control
(EM-95). After IPTG incubation or mAb stimulation, cells were
lysed in 1% SDS, 2% 
 
b
 
-ME, and 62.5 mM Tris, pH 6.8. Total
cell lysates were separated by SDS-PAGE and electroblotted onto
nitrocellulose membranes. To determine dependence of degrada-
tion on cellular proteasome activity, expression-matched WT-
hCD40– or hCD40-LMP1–expressing M12.4.1 cells (10
 
7
 
) were
preincubated for 2 h in the presence of either 50 
 
m
 
M MG132
(33) or DMSO vehicle at a concentration of 10
 
6
 
 cells/ml. Cells
were then stimulated with either 1 
 
m
 
g/ml anti-hCD40 (G28-5),
mouse IgG
 
1
 
 isotype control (MOPC-21), anti-mCD40 (1C10),
or rat IgG
 
2a
 
 isotype control (EM95.3) mAbs for 2 h. Cells in
I
 
k
 
B
 
a
 
 control experiments were stimulated for 20 min as maximal
depletion was previously demonstrated at this time point (29).
TRAF degradation by signaling via CD40 mutants was deter-
mined by stimulating WT-hCD40, hCD40
 
D
 
22, or hCD40-
T234A–expressing M12.4.1 cells for 10 min, 20 min, or 2 h with
1 
 
m
 
g/ml anti-hCD40 (G28-5) or isotype control (MOPC-21)
mAbs.
 
TRAF Recruitment to Receptors in Detergent-insoluble Fractions.
 
To determine TRAF movement into detergent-insoluble frac-
tions, WT-hCD40– or hCD40-LMP1– expressing M12.4.1 cells
(10
 
7
 
) were stimulated for 10 min in 1 ml with either 1 
 
m
 
g anti-
hCD40 (G28-5) or mouse IgG
 
1
 
 isotype control (MOPC-21)
mAbs. Cells were lysed in Brij lysis buffer (1% Brij 58, 150 mM
NaCl, and 20 mM Tris, pH 7.5) containing protease and phos-
phatase inhibitors for 30 min on ice. Detergent-soluble fractions
were separated by centrifugation and the detergent-insoluble pel-
let was isolated. The pellet was resuspended and sonicated in
buffer containing SDS to dissolve membrane rafts (0.5% SDS, 1%
 
b
 
-ME, 1% Brij 58, 150 mM NaCl, and 20 mM Tris, pH 7.5).
Detergent-soluble and -insoluble fractions for each condition
were separated by SDS-PAGE and electroblotted onto nitrocel-
lulose membranes. Density gradient separation of raft fractions
used ultracentrifugation (200,000 
 
g
 
 for 4 h at 4
 
8
 
C) of cells lysed as
above, then loaded onto a step gradient of 25, 21.5, 18, 15, and
8% Nycodenz (Amersham Pharmacia Biotech), as described pre-
viously (23). 11 fractions collected after centrifugation were sub-
jected to SDS-PAGE and Western blotting, as above. A chemilu-
minescent substrate (Pierce Chemical Co.) was used to detect
HRP-labeled Abs on Western blots for this and all additional
Western blots.
 
Electrophoretic Mobility Shift Assays and JNK Activation.
 
To
measure nuclear translocation of NF-
 
k
 
B and Sp1, WT-hCD40–
or hCD40-LMP1–expressing M12.4.1 or CH12.LX cells (10
 
7
 
)
were stimulated for 30, 60, and 120 min with either 1 
 
m
 
g/ml
anti-hCD40 (G28-5), mouse IgG
 
1
 
 isotype control (MOPC-21),
anti-mCD40 (1C10), or rat IgG
 
2a
 
 isotype control (EM95.3)
mAbs at a concentration of 10
 
6
 
 cells/ml. Nuclear extracts were
prepared and electrophoretic mobility shift assays (EMSAs) per-
formed as described previously (34). The probe for NF-
 
k
 
B was
described previously (34); the Sp1 probe was the gift of Dr. W.
Maury (University of Iowa). Samples were separated on a 5% na-
tive polyacrylamide gel at a constant current of 20 mA and x-ray
film exposed to dried gels overnight at 
 
2
 
70
 
8
 
C.
To measure JNK activation, WT-hCD40– or hCD40-LMP1–
expressing M12.4.1 or CH12.LX cells (2 
 
3
 
 10
 
6
 
/ml) were stimu-
lated for 15 min (M12.4.1 transfectants) or 30 min (CH12.LX
transfectants) with either 1 
 
m
 
g/ml anti-hCD40 (G28-5), mouse
IgG
 
1
 
 isotype control (MOPC-21), anti-mCD40 (HM40-3), or
hamster IgM isotype control (G235-1) mAbs. Cells were also
stimulated with 0.6 M sorbitol (an osmotic stress) as a positive 
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control. The times chosen represent the point of maximal JNK
activation for each of these cell lines, determined in previous
studies. Cell lysates were prepared and JNK activity measured as
described previously (29). Reactions were separated by SDS-
PAGE, and phosphorylated c-Jun was visualized by autoradiogra-
phy of dried gels.
 
Assays for B Cell Effector Functions.
 
To evaluate the upregula-
tion of surface proteins in B cells expressing inducible WT-
LMP1 or LMP1-hCD40 molecules, stable transfectants of
M12.4.1 cells were incubated with 100 
 
m
 
M IPTG. To analyze li-
gation-induced surface molecule upregulation, 5 
 
3
 
 10
 
5
 
 WT-
hCD40– or hCD40-LMP1–expressing M12.4.1 cells were stimu-
lated with either 100 ng/ml of anti-hCD40 (G28-5), mouse IgG
 
1
 
isotype control (MOPC-21), anti-mCD40 (1C10), or rat IgG
 
2a
 
isotype control (EM95.3) in 24-well plates. After 48–72 h, cells
were washed and stained with FITC-labeled Abs to surface pro-
teins or with isotype controls. Cells were then evaluated for sur-
face protein expression using a FACScan™ flow cytometer (Bec-
ton Dickinson).
IL-6 secretion was evaluated as described previously (7, 30).
Membrane-bound CD154 is required to induce B cell IL-6 se-
cretion (30). In brief, 10
 
5
 
 WT-hCD40– or hCD40-LMP1–
expressing CH12.LX cells were stimulated with either untrans-
fected CHO cells, CHO cells expressing mouse CD154, or
CHO cells expressing human CD154 at a 1:10 ratio (CHO cells/
B cells) in a 96-well microtitration plate for 48 h. IL-6 present in
the supernatant was detected by ELISA (7, 30).
CH12.LX and its transfected subclones express surface IgM
specific for phosphatidylcholine, an Ag found on the surface of
SRBCs (35). Enumeration of SRBC-specific IgM-secreting cells
was by direct plaque assay, as described previously (36). In brief,
1.5 
 
3
 
 10
 
3
 
 cells were stimulated in flat-bottomed 96-well plates in
a total volume of 200 
 
m
 
l for 72 h. Ab-secreting cells are measured
as cells capable of forming lytic plaques on a lawn of SRBCs in
the presence of complement, and are quantitated as plaque-form-
ing cells (PFCs) per 10
 
6
 
 viable cells recovered from replicate cul-
tures.
 
Results
 
To study potential differences in signaling by the cyto-
plasmic domains of CD40 and LMP1, stimulated by nor-
mal self-aggregation of the LMP1 membrane-spanning
domains, we constructed an inducible recombinant LMP1-
hCD40 gene encoding the NH
 
2
 
-terminal and transmem-
brane domains of LMP1 fused to the cytoplasmic CD40
domain. To study signaling events in a manner permitting
greater control over signal initiation and more precise
matching in protein expression, we also constructed a
hCD40-LMP1 gene encoding extracellular and transmem-
brane CD40 domains fused to the COOH-terminal cyto-
plasmic LMP1 domain. Two mouse B cell lines (M12.4.1
and CH12.LX) were stably transfected with either of these
constructs and signaling activity compared between WT-
LMP1 and the LMP1-hCD40 chimera and the wild-type
hCD40 and hCD40-LMP1 chimera, respectively. The cy-
toplasmic domains of mouse and hCD40 are similar in
structure and indistinguishable in function (19), and LMP1
functions in a similar manner in both mouse and human B
cells (7).
 
Induced TRAF Degradation by CD40 but Not LMP1.
 
We have reported previously that after CD40 stimulation,
the amounts of TRAF2 decrease in total cell lysates (23),
indicating that TRAFs may be degraded after initiation of
CD40 signaling. TRAF degradation may ultimately attenu-
ate a signal by CD40 and serve to regulate signaling by the
CD40 receptor. LMP1 also utilizes TRAF2 and TRAF3 in
its signaling pathway, so we wished to determine if this
degradation was also a feature of LMP1 signaling. Induced
expression of chimeric LMP1-hCD40 led to TRAF2 and
TRAF3 degradation as early as 6 h after IPTG induction
of receptor expression. In contrast, induced expression
of WT-LMP1 stimulated no demonstrable TRAF2 or
TRAF3 degradation for up to 24 h after IPTG induction,
although stimulation of these transfectants through endoge-
nous mouse CD40 (samples at right side of panels) led to
degradation of both TRAFs (Fig. 1, A and B). Induced ex-
Figure 1. TRAF degradation after induced expression of WT-LMP1
or LMP1-hCD40. (A) M12.4.1 B cells stably transfected with inducible
WT-LMP1 or LMP1-hCD40 were induced with IPTG for the indicated
number of hours, or stimulated with anti-mCD40 mAb or its isotype
control (iso; rightmost two lanes) for 2 h as described in Materials and
Methods. Total cell lysates were prepared, separated, and transferred to
nitrocellulose membranes as described in Materials and Methods. Western
blotting was performed to detect TRAF2 (A), TRAF3 (B), or actin as a
loading control (C). Numbers below each lane indicate densitometry val-
ues for the bands present in the lane. (D) Stable transfectants as in A were
treated with anti-mCD40 mAb, isotype control mAb, medium alone, or
IPTG for 72 h, before immunostaining for CD80. Staining and analysis
by immunofluorescence flow cytometry were performed as described in
Materials and Methods. Data are expressed as the percentage of change in
MCF of cells treated with anti-mCD40 mAb/isotype control mAb (black
bars) or treated with IPTG/B cell medium (white bars). Data are repre-
sentative of three independent experiments performed with two sets of
stably transfected subclones. 
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pression of LMP1 in this system has been previously shown
beginning at 6 h (7). Numbers below each lane indicate
densitometry values for the bands shown.
To permit a more direct comparison of the kinetics of
TRAF degradation stimulated via the CY domains of
CD40 and LMP1, we examined degradation after engage-
ment of the reverse chimeric molecules, WT-hCD40 or
chimeric hCD40-LMP1. Stable transfectants tested were
expression matched for these two molecules, as shown in
Fig. 6 A. TRAF2 and TRAF3 degradation is evident as
early as 10 min after ligation of WT-hCD40, but it is strik-
ingly absent after engagement of the hCD40-LMP1 chi-
 
mera for up to 6 h (Fig. 2, A and B). Addition of the 26S
proteasome inhibitor, MG132, led to a partial block in
TRAF2 and TRAF3 degradation induced by CD40 but
had little effect on TRAF2 and TRAF3 levels in hCD40-
LMP1–stimulated cells (Fig. 2, D and E). Simultaneously
stimulating B cells through both chimeric hCD40-LMP1
and the endogenous mouse CD40 led to an overall de-
crease in TRAF2 and TRAF3 levels (Fig. 2, D and E), in-
dicating that CD40-induced degradation predominates
over LMP1’s inability to induce degradation.
 
TRAF Degradation Requires Binding to CD40.
 
Several
reports have indicated that some CD40-mediated activa-
tion events are independent of TRAF2 and TRAF 3 bind-
ing (17, 19, 20, 30, 34, 37). To test whether CD40-
induced TRAF2 and 3 degradation could be occurring
independent of CD40 binding (as an indirect effect of
CD40 signaling), two mutants of CD40 were examined, a
22-amino acid deletion of the cytoplasmic tail of hCD40
(hCD40
 
D
 
22) and a point mutant in the PXQXT motif of
cytoplasmic hCD40 (hCD40T234A). These mutants are
defective in binding TRAFs 2 and 3 (20). To examine TRAF
degradation, WT-hCD40–, hCD40
 
D
 
22–, or hCD40T234A–
expressing M12.4.1 cells, matched for hCD40 surface ex-
pression (19), were stimulated with anti-hCD40 and total
lysates prepared. Stimulation of WT-hCD40 led to marked
decreases in TRAF2 and TRAF3, but this decrease was
noticeably absent after ligation of the hCD40
 
D
 
22 and
hCD40T234A mutants (Fig. 3, A and B). Analysis of
LMP1 cytoplasmic domain mutants, including a 53-amino
acid COOH-terminal truncation mutant, a deletion mu-
tant of the proximal COOH-terminal TRAF binding mo-
tif, and a point mutant in the distal COOH-terminal
TRAF binding motif did not identify mutants with an en-
hanced ability to degrade TRAFs (data not shown).
 
Recruitment of TRAFs into Membrane Rafts.
 
TRAFs are
adapter proteins that play a critical role in signaling by both
Figure 2. TRAF degradation after ligation of WT-hCD40 or hCD40-
LMP1. (A–C) Expression-matched M12.4.1 subclones stably transfected
with WT-hCD40 or hCD40-LMP1 were stimulated for the indicated
number of minutes or hours with anti-hCD40 or isotype control mAbs
(iso), as described in Materials and Methods. Total cell lysates were pre-
pared and analyzed as in the legend to Fig. 1, using blotting Abs specific
for (A) TRAF2, (B) TRAF3, or (C) actin. (D–G) Stable transfectants of
M12.4.1 cells expressing matched amounts of the molecules indicated at
the top of the lanes were stimulated for 2 h (D–F) or 20 min (G) with ei-
ther anti-hCD40, anti-mCD40, or isotype control mAbs appropriate for
each, as indicated to the left at the top of the figure. Where indicated,
stimulation was performed in the presence of the proteasome inhibitor
MG132. Total cell lysates were prepared and analyzed as above. Blotting
Abs were specific for (D) TRAF2, (E) TRAF3, (F) actin, and (G) IkBa.
Densitometric values are indicated below each band. Data presented are
representative of three independent experiments performed with two sets
of stably transfected subclones.
Figure 3. TRAF degradation requires direct binding to hCD40. Ex-
pression-matched M12.4.1 cell lines stably expressing WT-hCD40,
hCD40D22, or hCD40T234A were stimulated with either anti-hCD40
or isotype control mAbs (i) as described in Materials and Methods, for the
number of minutes indicated above the lanes. Total cell lysates were pre-
pared and separated as in previous figures, then analyzed by Western blot-
ting for (A) TRAF2, (B) TRAF3, or (C) actin. All cell lines used showed
similar TRAF degradation after ligation of their endogenously expressed
mCD40 molecules (not shown). Data are representative of three experi-
ments each performed with two sets of stably transfected subclones. 
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CD40 and LMP1, and different TRAFs may play different
roles in distinct signaling pathways (12, 20). We wished to
determine if differential TRAF utilization could explain
differences in TRAF degradation mediated via CD40 ver-
sus LMP1. LMP1 recruits TRAF3 to detergent-insoluble
membrane microdomains (membrane rafts; reference 22),
and we have shown previously that TRAF2 and TRAF3
are recruited with CD40 to membrane rafts (23). Mem-
brane rafts are cholesterol- and sphingolipid-enriched mi-
crodomains within the plasma membrane that may play a
role in concentrating receptors with signaling molecules
(for reviews, see references 38 and 39).
To examine CD40 or LMP1-induced recruitment of
TRAFs to rafts, the detergent insoluble fraction of cell ly-
sates was examined after stimulation through WT-hCD40
or hCD40-LMP1. Stimulated cells were lysed in 1% Brij-
58 and the insoluble pellet resuspended in 0.5% SDS and
sonicated, to obtain detergent soluble and insoluble frac-
tions. Ligation of both WT-hCD40 and hCD40-LMP1
initiated recruitment of TRAFs 2 and 3 to detergent-insol-
uble fractions (Fig. 4, A and B), although there were repro-
ducible differences in the relative amount of TRAF recruit-
ment. Specifically, WT-hCD40 stimulation appeared more
effective in inducing TRAF2 recruitment, whereas
hCD40-LMP1 stimulation appeared more effective in in-
ducing TRAF3 recruitment (Fig. 4, A and B). These differ-
ences were not due to clonal variation as endogenous
mCD40 stimulation in the hCD40-LMP1 transfected cell
line induced recruitment of TRAFs 2 and 3 as effectively as
did WT-hCD40 in cells expressing this molecule (data not
shown). Thus, it is possible that relative differences in the
amounts of TRAF recruitment contribute to differences
seen in TRAF degradation. However, as hCD40-LMP1
recruits more TRAF3 than does WT-hCD40, but does not
Figure 4. (A–C) TRAF recruit-
ment into detergent-insoluble frac-
tions by WT-hCD40 or hCD40-
LMP1. Expression-matched
M12.4.1 subclones stably trans-
fected with WT-hCD40 or hCD40-
LMP1 were stimulated for 10 min
with either anti-hCD40 (a-h) or
isotype control mAbs (iso), as de-
scribed in Materials and Methods.
Detergent-soluble (sol) and -insolu-
ble (insol) fractions of total cell ly-
sates were prepared as described in
Materials and Methods, separated by
SDS-PAGE, and analyzed by West-
ern blotting for recruitment of (A)
TRAF2 or (B) TRAF3. C was blot-
ted with anti-hCD40 to show the
presence of WT and chimeric recep-
tor molecules in the lysate fractions.
Data are representative of three
independent experiments. (D–K)
TRAF recruitment into membrane
rafts by hCD40-LMP1 or inducible
WT-LMP1. M12.4.1 subclones sta-
bly transfected with hCD40-LMP1
(D–G) were stimulated for 10 min
with either anti-hCD40 (E and G)
or isotype control mAb (D and F) as
described in Materials and Methods.
M12.4.1 subclones stably trans-
fected with inducible WT-LMP1
(H–K) were uninduced (H and J) or
induced with IPTG for 18 h (I and
K) as described in Materials and
Methods. Density gradient ultracen-
trifugation was performed as de-
scribed in Materials and Methods.
Cell lysate fractions were separated
by SDS-PAGE and analyzed by
Western blotting for LMP1 (D, E,
H, and I) or TRAF3 (F, G, J, and
K). Buoyant density of the fractions
collected decreases from left to right
as indicated above the blots. Data are
representative of three independent
experiments performed with two
sets of transfected subclones. 
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cause its degradation, it seems unlikely that TRAF recruit-
ment differences are important to differences in degrada-
tion. Both WT-hCD40 and hCD40-LMP1 receptors
themselves were recruited into detergent-insoluble fractions
after their stimulation, indicating that differences in mem-
brane raft localization of receptors are not responsible for
the observed differences in TRAF recruitment (Fig. 4 C).
Our previous studies have shown that Brij-58–insoluble
fractions of cell lysates correspond to high-buoyancy mem-
brane raft fractions isolated by density gradient centrifuga-
tion (23). To verify this in this study, lysates from unstimu-
lated (Fig. 4, D and F) or stimulated (Fig. 4, E and G) B
cells expressing hCD40-LMP1 were separated by density
gradient centrifugation, and fractions analyzed for CD40-
LMP1 and TRAF3. Fig. 4, H–K, shows the same analysis
performed on cells able to inducibly express WT-LMP1,
either in the absence (Fig. 4, H and J) or presence (Fig. 4, I
and K) of IPTG. Results corroborate those seen in Fig. 4,
A–C; stimulation of hCD40-LMP1 or induced expression
of WT-LMP1 induced their enhanced migration to mem-
brane raft fractions, together with recruitment of TRAF3.
 
Activation of NF-kB and JNK. Several signaling events
have been suggested to play important roles in CD40- and
LMP1-mediated B cell activation, including NF-kB and
JNK activation (17, 29, 40, 41). We wished to determine if
differences in TRAF degradation between CD40 and
LMP1 correlated with the capacity of these receptors to ac-
tivate these signaling pathways. To examine JNK activa-
tion, WT-hCD40 or hCD40-LMP1 transfectants were
stimulated with either anti-hCD40 or anti-mCD40 as an
internal control. Sorbitol stimulation (an osmotic stress)
was used as a positive control. After stimulation, an in vitro
kinase reaction was performed using a GST–c-Jun fusion
protein substrate as described previously (29). It can be seen
in Fig. 5 A that compared with stimulation with isotype
control mAb, stimulation through hCD40-LMP1 resulted
in two- to threefold greater c-jun phosphorylation than
stimulation through WT-hCD40.
To examine NF-kB activation, WT-hCD40 or hCD40-
LMP1 transfectants were stimulated with either anti-
hCD40 or anti-mCD40 as an internal control for various
times. After stimulation, EMSAs for NF-kB or Sp1 (as a
control) were performed. At early time points, WT-
hCD40 stimulation induced higher levels of NF-kB nu-
clear translocation than hCD40-LMP1 (Fig. 5 B), although
NF-kB activation stimulated by WT-hCD40 returned to
baseline values relatively rapidly. In contrast, translocated
NF-kB continued to increase after hCD40-LMP1 stimula-
tion (Fig. 5 B), demonstrating that the cytoplasmic domain
of LMP1 induced a more sustained signal. This higher level
of NF-kB activation was confirmed by reporter gene analy-
sis (not shown). No change in the amount of nuclear Sp1
was seen after either CD40 or LMP1 stimulation (Fig. 5 C).
Activation of B Cell Effector Functions. Induction of an
activated B cell phenotype, and B cell effector functions,
has been demonstrated after stimulation of CD40 or ex-
pression of LMP1 (4, 7, 19). We wished to determine if
differences in CD40- and LMP1-mediated TRAF degrada-
tion and early signaling events had functional implications
for the capacity of these receptors to activate B cells. B cell
activation was determined by surface molecule upregula-
tion, IL-6 secretion, and IgM secretion. Several surface
molecules are upregulated upon B cell activation, including
adhesion receptors such as ICAM-1, LFA-1, and CD23, as
well as costimulatory molecules such as B7. Signaling via
both CD40 and LMP1 upregulates these molecules (7, 19),
although a direct comparison between the capacity of the
two receptors to do so has not been possible previously.
Figure 5. Early B cell activation events triggered via WT-hCD40 vs.
hCD40-LMP1. (A) JNK activation. Expression-matched M12.4.1 sub-
clones stably transfected with WT-hCD40 or hCD40-LMP1 were stimu-
lated for 15 min with the positive control reagent sorbitol (S), anti-
hCD40 (a-h), anti-mCD40 (a-m), or isotype control mAbs for each
(iso1 and iso2, respectively). Stimulation conditions and in vitro kinase as-
says for the detection of JNK activation were performed as described in
Materials and Methods. Numbers below lanes labeled a-h are densitome-
try values of phosphorylated c-jun stimulated by anti-hCD40 mAb minus
values of samples stimulated with iso1. Numbers below lanes labeled a-m
are densitometry values of phosphorylated c-jun stimulated by anti-
mCD40 mAb minus values of samples stimulated with iso2. Data repre-
sent results of three independent experiments; similar results were ob-
tained in CH12.LX transfectants (not shown). (B) Nuclear translocation
of NF-kB. Expression-matched CH12.LX subclones stably transfected
with WT-hCD40 or hCD40-LMP1 were stimulated for the indicated
number of minutes with 1 mg/ml anti-hCD40 mAb. Control stimuli (de-
scribed in A) were given for 120 min. Cells were lysed and EMSA per-
formed as described in Materials and Methods. The lane labeled P con-
tained radioactive probe alone; the lane labeled CC contained a 10-fold
excess of unlabeled probe as a cold competitor. (C) Nuclear Sp1. EMSA
was performed on lysates as in B, using an Sp1-specific probe and cold
competitor. As in B, the lane labeled P indicates probe alone, and CC
contained a 10-fold excess of cold competing probe.950 Regulation of Signaling by CD40 and LMP1
M12.4.1 cells stably expressing matched levels of either
WT-hCD40 or hCD40-LMP1 (Fig. 6 A) were stimulated
for 48 h with either anti-hCD40 or anti-mCD40 as an in-
ternal control, and examined for surface expression of
ICAM-1, LFA-1, CD23, and B7-1. Anti-hCD40 stimula-
tion of hCD40-LMP1 transfectants resulted in greater cell
surface expression of all receptors examined, compared
with cells transfected with WT-hCD40 (Fig. 6 B). Differ-
ences in upregulation of surface molecule expression be-
tween cell lines were not seen after stimulation with anti-
mCD40 mAb, indicating these transfectants were equally
responsive. Mean channel fluorescence (MCF) values for
stimulation via mCD40 in the two stable transfectants
were: for hCD40-expressing cells, isotype control staining,
3.73; ICAM-1, 20.15; CD23, 5.71; LFA-1; 5.58, anti-
TNP control Ab, 4.47; B7-1, 5.42; hCD40-LMP1–
expressing cells, isotype control staining, 3.32; ICAM-1,
19.64; CD23, 5.34; LFA-1, 6.50; anti-TNP control Ab,
4.86; and B7-1, 5.00. To ensure that differences in effector
function were seen whether or not the LMP1 membrane-
spanning domains are present, the two chimeras described
for Fig. 1 were inducibly expressed and tested for their
ability to upregulate B7-1. Although it is not possible to
precisely match these cell lines for expression of the chi-
meric molecules, induction of WT-LMP1 expression led
to approximately twofold higher levels of B7-1 expression
compared with induction of the LMP1-hCD40 chimera
(Fig. 1 D), showing that stimulation via self-aggregation of
LMP1 leads to the same result as engagement of the exter-
nal domain of CD40.
We have demonstrated previously that, unlike most
CD40-induced B cell functions, production of IL-6 re-
quires stimulation with a membrane-bound form of
CD154 (30). To evaluate CD40- and LMP1-stimulated
IL-6 secretion, CH12.LX cells expressing equal levels of ei-
ther WT-hCD40 or hCD40-LMP1 were stimulated for
48 h with CHO cells expressing hCD154 (CHO-hCD154).
Untransfected CHO cells were a negative control and
CHO cells expressing mouse CD154 were an internal pos-
itive control. Stimulation of CH12.LX cells expressing
hCD40-LMP1 resulted in approximately twofold greater
IL-6 production than cells expressing WT-hCD40 (Fig. 6
C). No differences were seen between WT-hCD40– and
hCD40-LMP1–expressing cells after stimulation with
CHO cells expressing mCD154 (Fig. 6 C, middle bars).
Both CD40 engagement and LMP1 expression induce B
cell IgM secretion (7, 42), and CH12.LX cells provide an
excellent model for studying induced IgM production, as
they inducibly secrete IgM specific for a known antigen,
phosphatidylcholine (35). CH12.LX cells expressing either
WT-hCD40 or hCD40-LMP1 were stimulated with anti-
gen (SRBCs as a source of membrane phosphatidylcho-
line), with or without anti-hCD40 or anti-mCD40 as an
internal control. Stimulation of CH12.LX cells through
hCD40-LMP1 resulted in approximately four- to fivefold
greater secretion of IgM than cells stimulated through WT-
Figure 6. B cell effector functions stimulated by WT-
hCD40 vs. hCD40-LMP1. (A) Expression of transfected
WT-hCD40 and hCD40-LMP1 in B cell lines. M12.4.1
transfectants were analyzed by immunofluorescence flow
cytometry as described in Materials and Methods, using
anti-hCD40 (dotted lines) or isotype control (solid lines)
mAbs. All transfectants used in this study, including those
in CH12.LX cells, were expression matched in this man-
ner. (B) Summary data of increased surface molecule ex-
pression after ligation of WT-hCD40 (white bars) or
hCD40-LMP1 (black bars). Transfected M12.4.1 B cells
were stimulated with anti-hCD40 or isotype control
mAbs for 48 h as described in Materials and Methods.
Cells were then analyzed by immunofluorescence flow cy-
tometry as above, using FITC-labeled mAbs to ICAM-1,
CD23, LFA-1, or B7-1. Two isotype control mAbs were
used for staining; Con 1 is the isotype control for mAbs
specific for ICAM-1, CD23, and LFA-1; Con 2 is the
control for B7-1 staining. Data are presented as percentage
of change in MCF, calculated as MCF of cells stimulated
with anti-hCD40/MCF of cells stimulated with control
mAbs. Data are representative of three independent exper-
iments, using two sets of stably transfected subclones of B
cells. (C) IL-6 secretion induced via WT-hCD40 or
hCD40-LMP1. Expression-matched CH12.LX transfect-
ants were stimulated with either untransfected CHO cells
(white bars), CHO transfectants expressing mouse CD154
(horizontally striped bars), or CHO transfectants express-
ing human CD154 (vertically striped bars). Conditions of
stimulation and details of the IL-6 ELISA assay are described in Materials and Methods; values presented are the mean 6 SE of triplicate samples. Data
are representative of three independent experiments each for two sets of transfected B cell subclones. (D) IgM secretion induced via WT-hCD40 or
hCD40-LMP1. Expression-matched CH12.LX transfectants were stimulated with Ag (SRBC) alone (checked bars; not visible due to low values on this
scale), anti-mCD40 (horizontally striped bars), anti-mCD40 plus Ag (vertically striped bars), anti-hCD40 (black bars), or anti-hCD40 plus Ag (white
bars). The SRBC-specific plaque-forming cell (PFC) assay was performed as described in Materials and Methods. Values represent mean 6 SE of repli-
cate samples, and are representative of two independent experiments each for two sets of transfected B cell subclones.951 Brown et al.
hCD40 (Fig. 6 D). Secreted IgM levels were somewhat
higher with anti-mCD40 stimulation in WT-hCD40–
expressing cells than in hCD40-LMP1–expressing cells,
suggesting differences may be even greater. As described
previously (7), both CD40 and LMP1 stimulation synergize
with stimulation by antigen through the B cell receptor
(Fig. 6 D, white bars).
Discussion
Both CD40 and LMP1 stimulate B cell activation and
NF-kB/JNK activation (7, 29, 41, 43). Previous studies
have shown that the cytoplasmic domain of LMP1 is nec-
essary and sufficient to deliver these activation signals (7,
26, 41, 44), and have suggested that the LMP1 cytoplasmic
domain can mimic that of CD40 (5, 45), the major differ-
ence between the two being that LMP1 signals constitu-
tively via self-aggregation, whereas CD40 requires engage-
ment by CD154. However, several reports have also
presented evidence that important differences exist be-
tween the signaling pathways used by CD40 and LMP1.
LMP1 expression in the Jurkat T cell line stimulates detect-
able CD54 upregulation, whereas CD40 does not (44), and
transgenic B cell expression of LMP1 in CD402/2 mice
does not restore the normal development of B cell memory
(8). Additionally, earlier studies from our laboratory
showed that CD40 and LMP1 signals can cooperate in B
cell activation, further supporting the concept that the two
receptors use overlapping but distinct mechanisms of sig-
naling (7).
A very early event associated with signaling by both
LMP1 and CD40 is the recruitment of the cytoplasmic
adapter proteins TRAFs 1, 2, and 3 to cholesterol-rich, de-
tergent-insoluble membrane microdomains, or rafts (22,
23). We have recently shown that degradation of TRAF 2
rapidly follows CD40-mediated raft recruitment (23), a
finding we have confirmed in normal splenic B cells (un-
published observations). Although TRAF1 is also recruited
to rafts by both CD40 and LMP1, signaling through nei-
ther molecule stimulates any detectable degradation of
TRAF1 (data not shown). To determine whether LMP1
also stimulates degradation of TRAFs 2 and 3, we used an
inducibly expressed LMP1 molecule that we previously
found stimulates NF-kB activation and B cell effector
functions (7). Unlike CD40, self-aggregation of WT-
LMP1 stimulated no detectable TRAF degradation. This
was not due to a deficiency in the strength of the self-aggre-
gation stimulus compared with normal ligand-induced
aggregation of CD40, as a chimeric molecule with the
membrane-spanning domains of LMP1 and the cytoplas-
mic domain of CD40 induced TRAF degradation as effec-
tively as did WT CD40 (Fig. 1 versus Fig. 2).
The failure of LMP1 to mimic CD40 in stimulating the
degradation of TRAFs 2 and 3 led us to ask whether this
difference is reflected in altered signal strength or duration
in downstream effects on B cell activation. Although both
CD40 engagement and induced LMP1 expression have
been shown to stimulate increased expression of CD80 (7),
it is not possible to directly compare this effect between
WT CD40 and LMP1, because the modes of initiation of
the stimulus are quite different. However, when signaling
through the cytoplasmic domains of WT-LMP1 and
LMP1-hCD40 molecules was initiated for both molecules
by self-aggregation of the LMP1 membrane-spanning do-
mains, induced WT-LMP1 expression stimulated greater
upregulation of CD80 than did induced expression of the
LMP1-hCD40 molecule (Fig. 1 B). This finding suggested
that the failure of LMP1 signaling to induce TRAF degra-
dation may contribute to enhanced B cell activation signals
delivered via LMP1. However, direct comparison of sig-
naling, particularly early signaling events, is difficult to
make between molecules with LMP1 external domains.
These molecules begin to signal as their B cell expression is
induced, so initiation of signaling cannot be carefully regu-
lated or synchronized between cell lines. Additionally, as
their relative expression must be determined by Western
blotting, a technique that is only semiquantitative, it is dif-
ficult to ensure that two different transfected cell lines are
expressing the same amounts of different LMP1 molecules.
As mentioned above, we and others have shown previ-
ously that the cytoplasmic domain of LMP1 is necessary
and sufficient for B cell activation signals, and Fig. 1 shows
that TRAF degradation behavior also maps to the cytoplas-
mic domain of CD40 versus LMP1. We thus produced a
chimeric molecule consisting of the external and trans-
membrane domains of human CD40 and the cytoplasmic
domain of LMP1. This molecule allows quantitation of cell
surface expression in transfectants by flow cytometry, and,
like CD40, does not signal unless and until it is engaged by
CD154 or anti-CD40 mAb. B cell transfectants were gen-
erated that were expression matched for either WT-
hCD40 or the hCD40-LMP1 chimera (Fig. 6 A). Ligation
of these two receptors led to the same outcome as self-
aggregation of LMP1 versus LMP1-hCD40; namely, WT-
hCD40 induced TRAF 2 and 3 degradation, whereas
hCD40-LMP1 did not (Fig. 2). These data validated the
use of the hCD40-LMP1 molecule to directly compare sig-
naling by the cytoplasmic domains of CD40 and LMP1.
The ability of an inhibitor of the cellular 26S proteasome to
diminish the CD40-induced TRAF degradation suggests
that the process of ubiquitination may be involved in the
degradation, a possibility we are currently investigating.
The inability of the LMP1 molecule to degrade TRAFs
2 and 3 cannot be solely accounted for by strength of
TRAF binding. Fig. 4 demonstrates that properties of
TRAF binding in B cells confirm previous in vitro binding
assays (16). That is, although CD40 appears to bind
TRAF2 more effectively, LMP1 shows stronger binding
than CD40 to TRAF3. However, CD40 signaling stimu-
lates degradation of both TRAFs, whereas LMP1 signaling
stimulates degradation of neither. This suggests that there
may be a specific alteration induced in TRAFs 2 and 3 by
association with CD40, but not LMP1. This idea is sup-
ported by two pieces of evidence. First, although we and
others have shown that certain CD40-mediated activation
signals are independent of the binding of TRAFs 2 and 3952 Regulation of Signaling by CD40 and LMP1
(17, 19, 20, 30, 34, 46), data presented in Fig. 3 show that
hCD40 mutants that cannot bind TRAFs 2 or 3 cannot
stimulate TRAF degradation. Second, Fig. 2 shows that
when B cells receive signals from both CD40 and LMP1
cytoplasmic domains, TRAFs 2 and 3 are degraded. Thus,
LMP1 signaling does not block CD40-mediated TRAF
degradation, although in these transfectants the hCD40-
LMP1 molecule is expressed at higher levels than the en-
dogenous mCD40 molecule (not shown). This finding ar-
gues against the hypothesis that additional intracellular
molecules that bind to LMP1 but not CD40, such as
TNFR-associated death domain (TRADD), block TRAF
degradation. Additionally, LMP1 mutant molecules lacking
the TRADD binding site do not gain the ability to degrade
TRAFs (unpublished observations). However, intracellular
molecules that associate with CD40 but not LMP1 may
participate in the differential ability to degrade TRAFs 2
and 3. For example, CD40 but not LMP1 binds TRAF6,
and CD40 utilizes TRAF6 in several of its signaling func-
tions (15, 47, 48). We are currently examining the poten-
tial role of TRAF6 and other intracellular molecules in me-
diating degradation of TRAFs 2 and 3 by CD40 signals.
The model system described in this report permitted a
direct comparison of the effects of signaling via CD40 and
LMP1 on early B cell activation and later B cell effector
functions, and allowed us to determine whether the differ-
ential ability to degrade TRAFs 2 and 3 was reflected by
differences in downstream signaling through CD40 and
LMP1. Analysis in both M12.4.1 and CH12.LX transfec-
tants indicated that the cytoplasmic domain of LMP1 was a
more potent stimulus for JNK activation, a very early event
after initiation of signaling through each of these mole-
cules. Additionally, NF-kB activation was considerably
sustained in cells signaled via the LMP1 cytoplasmic do-
main compared with those signaled via WT-hCD40 (Fig.
5). Both JNK and NF-kB activation have been shown to
play important roles in signaling by both CD40 (for a re-
view, see reference 49) and LMP1 (18, 41, 50). To deter-
mine whether enhancement in these early signals correlated
with enhanced B cell effector functions, we compared sur-
face molecule upregulation, IL-6 and IgM secretion in-
duced by ligation of either WT-hCD40 or hCD40-LMP1,
and found that for all three effector functions, the LMP1
cytoplasmic domain provided a markedly greater stimulus
than that of CD40 (Fig. 6).
This study identifies a novel and important mechanism
by which TRAF signaling and thereby the signaling of re-
ceptors that utilize TRAFs may be regulated. The potential
importance of these results is underscored by the fact that
LMP1 is a transforming protein (2). Previous reports have
concluded that the transforming effect of LMP1 on B cells
is mostly due to its constitutive CD40 mimicry (see above).
The data presented here suggest that the capacity of LMP1
to transform cells may also be due to the maintenance of an
amplified and sustained LMP1 signal, permitted by avoid-
ing TRAF degradation. As the TRAF binding region of
LMP1 appears to play a necessary and sufficient role in cel-
lular transformation by LMP1 (51, 52), stimulation through
CD40 may be able to ultimately attenuate LMP1 signaling
by degrading the TRAFs necessary for its transforming ef-
fect. This hypothesis is supported by experimental data in-
dicating CD40 signals protect EBV-infected human pe-
ripheral B cells from undergoing transformation in vitro
and in vivo (53).
In summary, we have identified a novel mechanism for
regulating CD40 signaling. This mode of regulation in-
volves rapid proteasome-dependent degradation of TRAF
adapter molecules after initiation of signaling through
CD40. Strikingly, this mode of regulation is absent after
initiation of signaling through LMP1, possibly contributing
to the enhanced signaling potency of LMP1 and its ability
to transform B cells.
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